CARB-X

CARB-X
Name	CARB-X
Type	Public–private partnership
Founded	2016
Headquarters	Boston, Massachusetts
Area served	Global
Focus	Antibacterial innovation, antibiotic resistance, drug development

CARB-X is a global public–private partnership that funds and accelerates preclinical antibacterial research and development targeting antibacterial resistance. It operates at the intersection of pharmaceutical innovation, public health, and biodefense, supporting small biotechnology firms, academic groups, and nonprofit developers to advance novel antibiotics, vaccines, diagnostics, and other therapeutics toward clinical trials. CARB-X works with a network of funders, regulators, research institutions, and philanthropic organizations to address the clinical and public health threats posed by resistant bacterial pathogens.

Overview

CARB-X functions as an accelerator for early-stage antibacterial products, offering non-dilutive funding, technical assistance, and regulatory support to project teams. It selects projects across modalities including small molecules, biologics, bacteriophages, adjunctive therapies, and point-of-care diagnostics. Operating from offices linked to academic and research institutions, the partnership collaborates with stakeholders in global health, biodefense, and pharmaceutical development to reduce barriers that small innovators face in translating laboratory discoveries to human trials.

History and Funding

CARB-X was launched in 2016 through a coalition of foundations, governments, and research agencies. Initial and subsequent funders have included major philanthropic organizations, national agencies from multiple countries, and intergovernmental bodies. Its governance and funding model draw on precedents set by large-scale biomedical initiatives and partnerships among industrial and philanthropic actors. Over successive funding rounds, CARB-X expanded its scope and capital commitments, aligning with priority lists and guidance produced by leading public health and scientific bodies.

Mission and Strategic Priorities

CARB-X aims to accelerate the development of antibacterial products that address unmet medical needs caused by resistant pathogens. Strategic priorities include targeting critical pathogens, supporting innovative modalities, enabling rapid diagnostics, and strengthening global access and stewardship frameworks. The initiative coordinates with entities involved in priority-setting, regulatory policy, and procurement to ensure funded products meet clinical, public health, and market needs.

Programs and Portfolio

CARB-X manages a portfolio of funded projects spanning discovery, preclinical development, and early clinical-enabling work. Programmatic elements include grant evaluation, milestone-driven award management, technical and regulatory mentorship, and support for manufacturing scale-up. The portfolio reflects diverse approaches: novel antibiotics with new mechanisms of action, antimicrobial peptides, phage therapies, microbiome-based interventions, monoclonal antibodies, rapid point-of-care diagnostics, and adjuvant therapies to restore antibiotic efficacy.

Partnerships and Collaborations

CARB-X partners with national and international institutions, philanthropic foundations, academic centers, and private sector companies. It coordinates with regulatory agencies, procurement organizations, and clinical research networks to align preclinical development with clinical and regulatory expectations. Collaborators include universities, contract research organizations, industrial partners, and global health agencies focused on reducing antimicrobial resistance and improving access to effective therapies.

Impact and Outcomes

Through funding and technical assistance, CARB-X has advanced numerous candidate products into clinical development and enabled technologies to reach regulatory and manufacturing milestones. Outcomes include the progression of novel antibiotics and diagnostics from laboratory proof-of-concept to later-stage trials, strengthened capacity among funded developers, and contributions to a broader ecosystem supporting antibacterial innovation. The initiative has influenced priority-setting and served as a model for targeted, milestone-driven financing in emerging infectious disease countermeasure development.

Category:Antimicrobial resistance Category:Biotechnology organizations